Anthropic Pays $400M for a 10-Person Biotech Startup
Anthropic acquired Coefficient Bio — fewer than 10 employees, eight months old — for $400 million in stock. The play: making Claude the default AI for drug discovery.
Tag
Anthropic acquired Coefficient Bio — fewer than 10 employees, eight months old — for $400 million in stock. The play: making Claude the default AI for drug discovery.
Partnering with Anthropic, Ultima Genomics, and PacBio, the startup aims to sequence 100 million species and train AI models that can design therapeutics from a disease prompt.
Multiple biotech companies are sprinting to bring the first fully AI-designed antibody drugs to human testing. Here's how they're doing it and what it could mean for medicine.
New DNA construction technique improves error rates by 10,000x, enabling practical genome-scale synthesis for medicine and biotech
Ecotone AI's open-source framework makes population-scale DNA analysis economically viable for the first time.
Nature Biotechnology paper describes 'in silico team science' where AI agent collectives handle literature review, hypothesis generation, and data analysis
Google DeepMind spinoff claims its unified AI system can identify hidden binding sites and predict drug interactions faster than physics-based methods